Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Passaro, Antonio; Wang, Jing; Wang, Yan; Lee, S.-H.; Melosky, Barbara; Shih, Jin‐Yuan; Wang, Jing; Azuma, K.; Juan, Óscar; Cobo, Manuel; Felip, Enriqueta; Girard, Nicolas; B. Cortot, Alexis; Califano, Raffaele; Cappuzzo, Federico; Owen, Scott; Popat, Sanjay; Le Tan, Ju; Salinas, Jorge; Tomasini, Pascale; D. Gentzler, Ryan; N. William, William; L. Reckamp, Karen; Takahashi, Toshiaki; Ganguly, Sandip; M. Kowalski, Dariusz; Bearz, Alessandra; Mackean, Melanie; Barala, P.; B. Bourla, Ariel; Girvin, Angela; Greger, James; Millington, Dawn; Withelder, Monica; Xie, John; Sun, Tao; Shah, Shalin; Diorio, B.; E. Knoblauch, Roland; Bauml, Joshua; García Campelo, Rosario; Chul Cho, Byoung

doi:10.1016/j.annonc.2023.10.117

Public

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Published in Annals of Oncology • Oct 23, 2023

Authors:

Antonio Passaro

Jing Wang

Yan Wang

Abstract

BACKGROUND: Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) in phase I studies. These combinations were evaluated...

Subject

Medicine

Carboplatin

Chemotherapy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!